Chemomab Therapeutics (CMMB) Times Interest Earned (2017 - 2025)
Chemomab Therapeutics posted quarterly Times Interest Earned of $160.57 for Q4 2025, up 59.45% year-on-year from $100.71 in Q4 2024, and up 788.21% on a QoQ basis from $18.08 in Q3 2025.
Chemomab Therapeutics (CMMB) has 7 years of Times Interest Earned data on file, last reported at $160.57 in Q4 2025.
- For the quarter ending Q4 2025, Times Interest Earned rose 59.45% year-over-year to $160.57; the trailing twelve-month figure through Dec 2025 stood at -$96.87 (down 108.62% YoY), and the FY2025 full-year result was $16.73, down 9.9% from the prior year.
- Times Interest Earned for Q4 2025 stood at $160.57, up from $18.08 in the prior quarter.
- Across five years, Times Interest Earned topped out at $160.57 in Q4 2025 and bottomed at -$33.09 in Q3 2022.
- The 4-year median for Times Interest Earned is $18.08 (2025), against an average of $26.4.
- Peak annual rise in Times Interest Earned reached 1553.62% in 2024, while the deepest fall reached 21.22% in 2024.
- A 4-year view of Times Interest Earned shows it stood at -$20.74 in 2022, then jumped by 66.6% to -$6.93 in 2023, then surged by 1553.62% to $100.71 in 2024, then soared by 59.45% to $160.57 in 2025.
- The last three Times Interest Earned figures came in at $160.57 (Q4 2025), $18.08 (Q3 2025), and $100.71 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | 160.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 160.57 |
| Sep 30, 2025 | 18.08 |
| Dec 31, 2024 | 100.71 |
| Sep 30, 2024 | 16.34 |
| Jun 30, 2024 | 27.50 |
| Mar 31, 2024 | 22.49 |
| Dec 31, 2023 | -6.93 |
| Sep 30, 2023 | -16.90 |
| Jun 30, 2023 | 31.64 |
| Mar 31, 2023 | 28.55 |
| Dec 31, 2022 | -20.74 |
| Sep 30, 2022 | -33.09 |
| Jun 30, 2022 | 15.03 |
| Jun 30, 2019 | -1.60 |
| Dec 31, 2018 | -2.24 |
| Jun 30, 2018 | 5.16 |
| Dec 31, 2017 | -40.04 |